292 related articles for article (PubMed ID: 32476465)
21. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
22. Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial.
Washam JB; Hohnloser SH; Lopes RD; Wojdyla DM; Vinereanu D; Alexander JH; Gersh BJ; Hanna M; Horowitz J; Hylek EM; Xavier D; Verheugt FWA; Wallentin L; Granger CB;
J Thromb Thrombolysis; 2019 Apr; 47(3):345-352. PubMed ID: 30790160
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation.
Yoshimura A; Iriki Y; Ichiki H; Oketani N; Okui H; Maenosono R; Namino F; Miyata M; Ohishi M
J Cardiol; 2017 Jan; 69(1):228-235. PubMed ID: 27131792
[TBL] [Abstract][Full Text] [Related]
24. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
[TBL] [Abstract][Full Text] [Related]
25. A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial.
Reynolds MR; Allison JS; Natale A; Weisberg IL; Ellenbogen KA; Richards M; Hsieh WH; Sutherland J; Cannon CP
JACC Clin Electrophysiol; 2018 May; 4(5):580-588. PubMed ID: 29798783
[TBL] [Abstract][Full Text] [Related]
26. Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease.
Altawalbeh SM; Alshogran OY; Smith KJ
Value Health; 2018 Dec; 21(12):1365-1372. PubMed ID: 30502779
[TBL] [Abstract][Full Text] [Related]
27. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
Chan YH; See LC; Tu HT; Yeh YH; Chang SH; Wu LS; Lee HF; Wang CL; Kuo CF; Kuo CT
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622587
[TBL] [Abstract][Full Text] [Related]
29. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
[TBL] [Abstract][Full Text] [Related]
30. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
31. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.
van Nieuwenhuizen KM; van der Worp HB; Algra A; Kappelle LJ; Rinkel GJ; van Gelder IC; Schutgens RE; Klijn CJ;
Trials; 2015 Sep; 16():393. PubMed ID: 26340977
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
33. Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study.
Liu T; Yang HL; Gu L; Hui J; Omorogieva O; Ren MX; Wang XH
BMC Cardiovasc Disord; 2020 Jan; 20(1):22. PubMed ID: 31948390
[TBL] [Abstract][Full Text] [Related]
34. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
Desai NR; Krumme AA; Schneeweiss S; Shrank WH; Brill G; Pezalla EJ; Spettell CM; Brennan TA; Matlin OS; Avorn J; Choudhry NK
Am J Med; 2014 Nov; 127(11):1075-1082.e1. PubMed ID: 24859719
[TBL] [Abstract][Full Text] [Related]
35. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial.
Dalgaard F; Mulder H; Wojdyla DM; Lopes RD; Held C; Alexander JH; De Caterina R; Washam JB; Hylek EM; Garcia DA; Gersh BJ; Wallentin L; Granger CB; Al-Khatib SM
Circulation; 2020 Jan; 141(1):10-20. PubMed ID: 31747786
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
Shah A; Shewale A; Hayes CJ; Martin BC
Stroke; 2016 Jun; 47(6):1555-61. PubMed ID: 27103018
[TBL] [Abstract][Full Text] [Related]
37. Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference?
Ionescu F; Cooper C; Petrescu I; George J; Mansuri S
Eur J Haematol; 2021 May; 106(5):689-696. PubMed ID: 33569825
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
Hernandez I; Zhang Y; Saba S
Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
[TBL] [Abstract][Full Text] [Related]
39. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
[TBL] [Abstract][Full Text] [Related]
40. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
Kido K; Ngorsuraches S
Ann Pharmacother; 2019 Feb; 53(2):165-170. PubMed ID: 30130979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]